Enanta Pharmaceuticals Stock News

While a mid-stage study evaluating Enanta's (ENTA) RSV candidate misses out on its primary endpoint, a statistically huge number of subjects achieved undetectable RSV RNA at the end of treatment.

While a mid-stage study evaluating Enanta's (ENTA) RSV candidate misses out on its primary endpoint, a statistically huge number of subjects achieved undetectable RSV RNA at the end of treatment.

Keybanc cut PubMatic, Inc. (NASDAQ: PUBM) price target from $48 to $27. PubMatic shares fell 1.5% to $18.71 in pre-market trading. Mizuho raised the price target for Amgen Inc. (NASDAQ: AMGN) from

ENTA earnings call for the period ending March 31, 2022.

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -13.99% and 8.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q2 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Jennifer Viera - Director of IR & Corporate Communications Jay Luly - President

Xencor (XNCR) delivered earnings and revenue surprises of 155.71% and 302.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Tarrytown, New York, March 11, 2022 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA), the largest ear, nose, throat, allergy, and audiology practice in the nation, which continuously strives to encourage and promote the very best medical advancements in the fields of otolaryngology, immunology, and audiology announced today that it is currently participating in a nationwide clinical trial of a novel regenerative medicine designed to restore hearing in patients with acquired sensorineural hearing loss (SNHL). Led by ENTA''s fellowship-trained otologist/neurotologist Sujana Chandrasekhar, MD, FACS, its New York City office currently is enrolling subjects in a study of the drug candidate FX-322, being developed by Frequency Therapeutics. Frequency Therapeutics, Inc. is a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person''s innate regenerative potential to restore function. FX-322 is designed to regenerate cells in the ear lost to acquired SNHL and, to date, has shown hearing improvements in key measures of hearing function in three separate studies in which a single dose of FX-322 was administered.

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference

Open Orphan client Enanta Pharmaceuticals confirms positive results from human challenge study

Open Orphan PLC (AIM:ORPH, OTC:OPORF) has highlighted positive results of a human challenge study assessing Enanta Pharmaceuticals (NASDAQ:ENTA)' respiratory syncytial virus (RSV) antiviral candidate,

Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) has dosed the first subject in its Phase 1 trial of EDP-235 , a coronavirus 3CL protease inhibitor, specifically designed as a once-daily, oral treatment for COVID-19. The Company plans to report data from this study in Q2 of 2022, and, assuming positive findings, Enanta expects to advance EDP-235 to the … Full story available on Benzinga.com

Enanta Pharmaceuticals (ENTA) dosed the first person in its phase 1 trial of its oral COVID-19 therapy EDP-235.The phase 1 study will evaluate the EDP-235 in single ascending…

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Enanta Pharmaceuticals (NASDAQ: ENTA ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 5 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 1 0 0 2M Ago 0 0 0 0 0 3M Ago 0 2 3 0 0 According to 7 analyst offering 12-month price targets in the last 3 months, Enanta Pharmaceuticals has an average price target of $86.43 with a high of $116.00 and a low of $68.00. Below is a summary of how these 7 analysts rated Enanta Pharmaceuticals over the past 3 months. The greater the number of … Full story available on Benzinga.com